Multi-color CD34⁺ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia

详细信息	查看全文 | 推荐本文 |

• 作者：Guilin Tang^a ; Jeffrey L. Jorgensen^a ; Yi Zhou^a ; Ying Hu^a ; Marian Kersh^a ; Guillermo Garcia-Manero^b ; L. Jeffrey Medeiros^a ; Sa A. Wang^a ; ^{swang5@mdanderson.org}
• 关键词：Myelodysplastic syndromes ; Therapy-related ; Cytopenia ; Multi-color flow cytometry ; CD34+ progenitors ; Myelomonocytic cells
• 刊名：Leukemia Research
• 出版年：2012
• 期刊代码：186_01452126
• 类别：med
• 出版时间：August, 2012
• 卷：36
• 期：8
• 页码：974-981
• 文件大小：889 K

摘要

Bone marrow assessment for myelodysplastic syndrome (MDS) in a patient who develops cytopenia(s) following cancer therapy is challenging. With recent advances in multi-color flow cytometry immunophenotypic analysis, a CD34⁺ progenitor-focused 7-color assay was developed and tested in this clinical setting. This assay was first performed in 73 MDS patients and 53 non-MDS patients (developmental set). A number of immunophenotypic changes were differentially observed in these two groups. Based on the sensitivity, specificity and reproducibility, a core panel of markers was selected for final assessment that included increased total CD34⁺ myeloblasts; decreased stage I hematogones; altered CD45/side scatter; altered expression of CD13, CD33, CD34, CD38, CD117, and CD123; aberrant expression of lymphoid or mature myelomonocytic antigens on CD34⁺ myeloblasts; and several marked alterations in maturing myelomonocytic cells. The data were translated into a simplified scoring system which was then used in 120 patients with cytopenia(s) secondary to cancer therapy over a 2-year period (validation set). With a median follow-up of 11 months, this assay demonstrated 89%sensitivity, 94%specificity, and 92%accuracy in establishing or excluding a diagnosis of MDS.